Roots scores first RZTO sale in buzzing medical cannabis market

|

Published 01-NOV-2018 10:35 A.M.

|

3 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

Ag-tech pot-stock, Roots Sustainable Agricultural Technologies (ASX:ROO), has secured the first sale of its Root Zone Temperature Optimisation (RZTO) heating and cooling technology in the blooming medicinal marijuana market.

The sale follows directly on from promising interim proof-of-concept cooling results on medicinal cannabis planted in greenhouses during July, where cooled plants achieved a substantial increase in size and stem diameter compared to control crops in just two months, thanks to ROO’s RZTO technology.

ROO is creating disruptive, modular, cutting-edge technologies to solve major problems in modern agriculture, including plant climate management and the shortage of water for irrigation. Its patented RZTO technology optimises plant physiology for increased growth, productivity and quality by stabilising the plant’s root zone temperature.

During its world-first proof-of-concept in northern Israel, ROO's RZTO cooling system was used to keep the root zone of cannabis plants at more than 7 degrees below the root zones of the control crops and kept a favourable temperature range.

This was a collaboration with Canndoc Limited, one of Israel’s leading medical cannabis growers. These encouraging interim results look to offer sizeable value to farmers in the medicinal cannabis space — one that’s expected to reach US$55.8 billion by 2025.

Meanwhile, the initial order, which is valued at A$47,000, will see ROO installing its RZTO heating technology in four areas within the greenhouse: plant quarantine, mother plant, rooting greenhouse and growing-tables. This will be in central Israel, a fully legalised medical cannabis jurisdiction.

This latest development highlights the relevance and strength of the RZTO system on a variety of crops and conditions. It’s also in line with ROO’s marketing strategy that centres around initial pilots on select crops that lead to commercial orders.

“Roots’ first sale to the local cannabis sector so soon after the interim results were published highlights the sizeable opportunity this market presents for our heating and cooling technology,” Roots CEO and co-founder Dr. Sharon Devir said.

“We expect this order will be the first of many as we continue to demonstrate the benefits of root zone heating and cooling on cannabis crops in varying climates and growing conditions.

“This sale is a good example of the versatility and adaptability of Roots’ RZTO system on various crops, in protected agricultural as well as in open fields. It supports our step-by-step pilot-to-sales marketing approach of conducting pilots on select crops in various conditions to prove its efficiency.

“A hybrid system, it will comprise of ground source heat exchange coils and a heat pump to heat the roots during winter and cool them in summer, using very little energy at a fraction of the cost compared with traditional air heating and cooling systems.

“We believe this sale will support a growing body of evidence that our technology provides optimal growing conditions essential for achieving high yield and healthy plants,” she said.

This encouraging development comes on the heels of ample positive news flow from ROO. Last week, the company revealed it has sold its first RZTO system for use on basil crops in Israel — another situation in which an encouraging pilot has reinforced the efficacy of ROO’s razor-sharp tech in diverse conditions, thereby opening commercial doors and playing nicely into the aforementioned strategy.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X